Supplement.ge
Supplement.geSupplement.ge
Font ResizerAa
  • News
  • Safety & Recalls
  • Diseases
  • Symptoms
  • Supplement Database
  • About
Search
  • News
    • Ingredient Spotlight
    • Research & Science
    • Safety Alerts
    • Consumer Guide
    • Industry News
    • Clinical Trials
    • All News
  • Safety & Recalls
    • Product Recalls
    • FDA & EU Warnings
    • Mislabeling & Fraud
    • Supplement Scams
    • Food Recalls & Alerts
  • Diseases
  • Symptoms
  • Supplement Database
    • Ingredients
    • Brands
    • Products
    • Compare
    • Labels
    • Regulatory
  • About
    • About Supplement.ge
    • Methodology
    • Data Transparency
    • Contact
    • PHIG Network
Have an existing account? Sign In
Follow US
Ingredient SpotlightVitamins

Niacin (Vitamin B3): From Deficiency to Pharmacological Doses — A Clinical Review

Last updated: 12/11/2026 02:43
Irina Datashvili
Share
Cover graphic for "Niacin (Vitamin B3)": the article title set in white on a dark green background with a panel showing evidence grade B.
Cover: supplement.ge, CC BY 4.0. Evidence identifiers shown are the sources cited in this article.
SHARE
Grade B Evidence— Essential for NAD+ synthesis; pharmacological doses have cardiovascular history but AIM-HIGH failure limits current enthusiasm

Niacin occupies a unique position in nutritional pharmacology. It is simultaneously an essential B vitamin whose deficiency causes a devastating disease (pellagra), a drug that was for decades the most effective lipid-modifying agent available, and the molecule at the centre of one of the most commercially inflated promises in modern supplement marketing — the NAD+ longevity hypothesis. Each of these stories is worth understanding, because they involve the same compound behaving very differently depending on dose, form, and context. This article traces all three, drawing on the evidence with the rigour the topic deserves.

Niacin’s Many Faces: Nicotinic Acid, Nicotinamide, NR, and NMN

The term “niacin” or “vitamin B3” refers to a family of related compounds that all serve as precursors to nicotinamide adenine dinucleotide (NAD+) but have significantly different pharmacological profiles. Getting these distinctions right is essential before interpreting any trial data.

At pharmacological doses (1–3 g/day), nicotinic acid has powerful lipid-modifying effects: it raises HDL cholesterol, lowers triglycerides, and lowers LDL cholesterol. This made it the most prescribed lipid drug before statins. It is also the form with the most extensive and sobering clinical trial record.

Nicotinamide (niacinamide) is the amide form that does not cause flushing and does not have the lipid-modifying effects of nicotinic acid at equivalent doses. It is the form typically used in nutritional supplements and B-complex vitamins. It is efficiently converted to NAD+ in most tissues. The absence of the flush makes it far more tolerable.

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are newer forms positioned as more efficient NAD+ precursors that bypass some of the earlier steps in the biosynthesis pathway. They are marketed primarily as anti-ageing supplements based on animal studies showing that boosting NAD+ levels extends lifespan in model organisms. Human trials are underway but remain limited in size, duration, and clinical outcomes. These compounds do demonstrably raise tissue NAD+ levels in humans — the mechanistic premise is not in dispute — but whether this translates to meaningful clinical benefit remains unproven.

The Essential Role of NAD+: Why Every Cell Needs Niacin

To understand niacin’s importance, it helps to appreciate the centrality of NAD+ to cellular metabolism. NAD+ (and its reduced form NADH) is involved in hundreds of enzymatic reactions spanning energy metabolism, DNA repair, gene expression regulation, and cellular signalling. No living cell can function without it.

Energy metabolism: NAD+ is the electron acceptor in glycolysis, the citric acid cycle, and beta-oxidation of fatty acids. NADH generated in these processes donates electrons to the mitochondrial electron transport chain to generate ATP. This is not an optional pathway — it is the core of cellular respiration. The connection to NAD+ and mitochondrial function explains why severe niacin deficiency so quickly produces the multi-system failure seen in pellagra.

DNA repair: NAD+ is consumed as a substrate by PARP enzymes (poly ADP-ribose polymerases), which are activated by DNA strand breaks and are essential for the DNA damage response. PARP activity consumes enormous amounts of NAD+ when cells are under genotoxic stress, which is one reason NAD+ levels decline with age (cumulative DNA damage increases PARP activation) and one mechanistic rationale for the NAD+ replenishment hypothesis.

Sirtuins: The sirtuin family of deacylases (SIRT1–7) are NAD+-dependent enzymes that regulate protein acetylation, gene expression, mitochondrial biogenesis, and metabolic homeostasis. SIRT1 and SIRT3, in particular, have been extensively studied as longevity-associated proteins in model organisms. Because sirtuins consume NAD+ as a cofactor, they link NAD+ availability to transcriptional regulation — the mechanistic backbone of the NAD+ ageing hypothesis.

The body synthesises NAD+ through multiple pathways: de novo from tryptophan (the Preiss-Handler pathway), from dietary niacin forms, and through salvage pathways recycling nicotinamide. This redundancy means that most people eating a varied diet maintain adequate NAD+ without supplementation — but it also means that supplementation with any of several niacin forms can effectively raise NAD+ levels.

Pellagra: The Four Ds and the History of a Preventable Disease

Pellagra is the clinical syndrome of niacin deficiency, characterised by the classic “Four Ds”: Dermatitis, Diarrhoea, Dementia, and Death if untreated. It was epidemic in the early twentieth century in the American South and parts of Europe where maize-based diets without traditional alkaline processing (nixtamalisation) provided inadequate bioavailable niacin.

The dermatitis is a photosensitive rash appearing on sun-exposed skin — the face, neck (producing the characteristic “Casal’s necklace”), and dorsal hands. It is scaly, hyperpigmented, and bilaterally symmetrical. This cutaneous manifestation was what drew clinical attention in epidemic outbreaks and gave pellagra its name (from Italian pelle agra — rough skin).

The diarrhoea reflects gastrointestinal mucosal atrophy — niacin deficiency impairs the rapid cell turnover of gut epithelium, leading to malabsorption and watery diarrhoea that further worsens nutritional status in a vicious cycle.

The dementia — more accurately, a spectrum of neuropsychiatric symptoms including confusion, disorientation, anxiety, hallucinations, and psychosis — reflects the dependence of the central nervous system on NAD+ for neurotransmitter synthesis and neuronal energy metabolism. Many pellagra patients were institutionalised in psychiatric facilities before the nutritional aetiology was established.

The story of pellagra’s resolution is an important episode in the history of public health. Joseph Goldberger, a US Public Health Service physician, demonstrated in the 1910s and 1920s through elegant epidemiological investigations — including deliberately inducing pellagra in prison volunteers and curing it with dietary change — that it was a nutritional deficiency, not an infectious disease as most believed. His work was rejected for years by the medical establishment. Conrad Elvehjem subsequently identified nicotinic acid as the curative factor in 1937. Food fortification programmes, beginning in the 1940s, virtually eliminated pellagra from developed countries.

Today, pellagra still occurs in clinical contexts where niacin metabolism is disrupted: alcoholism (which depletes multiple B vitamins, including through impaired absorption and increased metabolic demand — analogous to thiamine depletion), isoniazid therapy (which interferes with B6 and indirectly niacin synthesis), carcinoid syndrome (which diverts tryptophan away from NAD+ synthesis), and severely restricted diets.

Pharmacological Niacin and Cardiovascular Disease: The Rise and Fall

The cardiovascular story of niacin is one of the more striking reversals in clinical medicine. For decades, nicotinic acid was considered not just useful but among the most potent lipid-modifying agents available — a status that made it a cornerstone of cardiovascular prevention before statins became dominant.

These effects are mediated through nicotinic acid’s action on adipocyte GPR109A receptors, reducing free fatty acid release from adipose tissue, which secondarily reduces hepatic VLDL synthesis.

Early trial success: The Coronary Drug Project (1966–1975) was the first large cardiovascular outcomes trial of niacin. It enrolled 8,341 men with prior myocardial infarction. The niacin arm showed a significant reduction in recurrent non-fatal MI, and the 15-year follow-up showed a mortality benefit that was retained even years after treatment was discontinued — one of the first examples of what would later be called a “legacy effect.” This trial established niacin as an evidence-based cardiovascular treatment.

The subsequent widespread use of niacin — often combined with statins to target the residual HDL and triglyceride risk after LDL was controlled — seemed well-justified by mechanism and early data. The question was whether adding niacin to statin therapy would produce incremental cardiovascular benefit beyond what statins alone achieved.

The AIM-HIGH Trial: Why Niacin Failed to Reduce Heart Events

The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial was designed to answer the question definitively: does adding extended-release niacin to statin therapy further reduce cardiovascular events in patients with established cardiovascular disease and low HDL?

The trial enrolled 3,414 patients with cardiovascular disease, low HDL, and high triglycerides who were already on statins with LDL well-controlled. They were randomised to extended-release niacin (1,500–2,000 mg/day) or placebo. The niacin group achieved the expected lipid changes — HDL rose substantially, triglycerides fell, LDL fell further. The lipid effects were confirmed. The cardiovascular benefit was not.

AIM-HIGH was stopped early in 2011 — not because of harm, but because of futility. After 36 months, niacin showed no significant reduction in the primary composite endpoint (coronary heart disease death, non-fatal MI, ischaemic stroke, hospitalisation for acute coronary syndrome, or symptom-driven coronary or cerebral revascularisation). The hazard ratio was 1.02 — essentially no effect. Additionally, there was a non-significant trend toward increased ischaemic stroke in the niacin group.

The HPS2-THRIVE trial (2013) confirmed this finding in a much larger population (25,673 patients), adding extended-release niacin plus laropiprant (a drug that blocks the niacin flush) to statin therapy. This trial showed no reduction in cardiovascular events and a significant increase in serious adverse events — including unexpected increases in infections, bleeding, and musculoskeletal complications. The FDA subsequently withdrew approval for the niacin-laropiprant combination.

The interpretation of this data is debated. One view is that HDL cholesterol is not causally important for cardiovascular events — that it is a marker, not a mediator, and that raising it pharmacologically without addressing the underlying biology provides no benefit. Mendelian randomisation studies have generally supported this interpretation. Another view is that niacin’s additional mechanisms (raising lipoprotein(a), reducing small dense LDL) may still be relevant in specific subgroups not well-represented in AIM-HIGH. The clinical consensus has moved toward reserving pharmacological niacin for the rare patient with extremely high lipoprotein(a) or severe hypertriglyceridaemia unresponsive to other treatments, under specialist supervision.

As with vitamin B12 and other B vitamins, the evidence demonstrates that metabolic markers improving with treatment does not guarantee that clinically meaningful outcomes improve. The metabolic risk context matters enormously for how pharmacological interventions translate to patient outcomes.

The Niacin Flush: Mechanism, Management, and No-Flush Alternatives

The niacin flush is not a harmful side effect — it is a pharmacological mechanism. Nicotinic acid activates the GPR109A receptor on Langerhans cells in the skin, triggering prostaglandin D2 synthesis, which causes cutaneous vasodilation. The result is reddening, warmth, tingling, and sometimes pruritus affecting the face, neck, and upper chest, typically beginning 15–30 minutes after ingestion and lasting 30–90 minutes.

While harmless, the flush is the principal reason for poor compliance with nicotinic acid therapy.

Inositol hexanicotinate is marketed as “no-flush niacin” and is widely sold as a supplement. It is hydrolysed slowly to free nicotinic acid and inositol after absorption. Despite the marketing, well-designed pharmacokinetic studies show that inositol hexanicotinate produces only trivial amounts of free nicotinic acid in the circulation — concentrations far too low to produce the lipid effects seen with equivalent doses of nicotinic acid. It does not flush because it does not substantially work as nicotinic acid. It may raise tissue NAD+ through the nicotinamide pathway, but it has no meaningful cardiovascular lipid-modifying activity.

Nicotinamide (niacinamide) also does not flush and is an effective NAD+ precursor for nutritional supplementation purposes, but similarly lacks the GPR109A-mediated lipid effects of nicotinic acid. If someone wants to supplement B3 for nutritional reasons rather than lipid modification, nicotinamide is a reasonable choice with a good safety profile up to several grams per day (though high doses can cause hepatotoxicity in susceptible individuals).

NR and NMN: The NAD+ Boosting Hype vs. Current Human Evidence

The NAD+ longevity hypothesis has generated enormous commercial interest in nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). The underlying biology is genuinely compelling: NAD+ levels decline with age in multiple tissues, and in model organisms from yeast to mice, restoring NAD+ through supplementation with these precursors has extended lifespan and healthspan, improved mitochondrial function, and enhanced metabolic markers. These are not trivial findings.

What human trials have shown so far: Multiple studies have confirmed that oral NR and NMN dose-dependently raise blood NAD+ levels in humans. This is not in dispute. A 250 mg dose of NR raises whole blood NAD+ by approximately 40–60%, and NMN shows similar or greater potency per gram. The question is whether these elevated NAD+ levels translate to any meaningful health outcome.

The clinical evidence to date is modest. Studies have generally been small (20–100 participants), short (8–12 weeks), and focused on surrogate biomarkers rather than hard clinical endpoints. Some findings of interest include: NR improving muscle mitochondrial function in a small trial of older adults; NMN improving muscle insulin sensitivity in older women; NR reducing inflammatory markers in some contexts; and mixed results on blood pressure, cognitive function, and body composition. No completed large-scale trial has demonstrated that NR or NMN prevents any clinically meaningful outcome — cognitive decline, cardiovascular events, cancer incidence, or longevity — in humans.

The gut microbiome interacts significantly with B-vitamin metabolism — some NMN is converted to nicotinamide by gut bacteria before absorption, raising questions about bioavailability that differ between individuals with different microbiome compositions. This adds complexity to dose-response relationships in human trials.

The honest assessment: NR and NMN are not fraudulent supplements with no mechanism. The science behind NAD+ and ageing is real and interesting. But the extrapolation from mouse lifespan studies and short-term human biomarker trials to meaningful anti-ageing effects in humans is a leap that the current evidence does not support. These are expensive supplements ($50–150/month) being marketed against a promise that remains scientifically unproven. This is a case where following the clinical evidence means maintaining scepticism while acknowledging genuine biological plausibility.

Practical Guide: Dietary Sources, RDA, and When Supplementation Makes Sense

Dietary sources: Niacin is widely distributed in the food supply and deficiency is rare in developed countries. Tryptophan in protein foods also contributes to NAD+ synthesis via the kynurenine pathway — dietary protein adequacy matters for overall niacin status.

Notably, the niacin in maize is largely bound in a form (niacytin) that is not bioavailable without alkaline treatment. Traditional Mesoamerican nixtamalisation — soaking maize in lime water — releases this bound niacin. When maize was adopted in Europe without this processing technique, pellagra followed. This historical lesson about food preparation and nutrient bioavailability remains relevant to discussions of whole food vs. supplement nutrition.

RDA and upper limits: The Recommended Dietary Allowance for niacin is 16 mg NE (niacin equivalents) per day for adult men and 14 mg NE for adult women. The Tolerable Upper Intake Level is 35 mg/day for adults from supplemental sources — a threshold set to prevent flushing and other adverse effects, not because toxicity occurs at this level. At pharmacological doses (1–3 g/day nicotinic acid), significant adverse effects can occur including hepatotoxicity (most concerning with slow-release formulations), hyperuricaemia, glucose intolerance, and gastrointestinal symptoms.

When supplementation makes sense:

  • Pellagra or confirmed deficiency — nicotinamide 100–300 mg/day corrects deficiency rapidly
  • Alcohol use disorder — B vitamin repletion is standard clinical practice
  • Isoniazid therapy — B6 and niacin supplementation is often recommended alongside this tuberculosis drug
  • Severe hypertriglyceridaemia — pharmacological nicotinic acid under specialist supervision when fibrates are insufficient
  • Non-melanoma skin cancer prevention in high-risk individuals — nicotinamide 500 mg twice daily showed 23% reduction in a RCT; this is a specific medical use
  • NR/NMN for ageing — not currently supported by sufficient evidence for routine recommendation
  • Source: reference intakes from the Institute of Medicine Dietary Reference Intakes; trial doses from the studies in the evidence base below.

Figures in this list are the recommendations of the guidelines and studies cited in this article; they are not independent findings.

As with other B vitamins reviewed in this series, niacin’s story is one of genuine essential roles, proven benefits in deficiency, pharmacological history that proved more complex than hoped, and a new chapter of mechanistically interesting but clinically unproven anti-ageing applications. Reading the evidence carefully rather than the marketing copy is the essential skill.

Frequently Asked Questions

What is the difference between niacin and niacinamide in skincare products?

In topical skincare, niacinamide (nicotinamide) is the form used — not nicotinic acid. Topical niacinamide has well-supported evidence for reducing hyperpigmentation (by blocking melanosome transfer to keratinocytes), improving skin barrier function, reducing sebum production, and decreasing fine lines. The flush-causing form (nicotinic acid) is not used topically for skincare. The distinction matters because “niacin” on a skincare label almost always means niacinamide, the non-flush form.

Should I take NMN or NR supplements?

There is no evidence-based recommendation to take NMN or NR for any specific health outcome currently. They demonstrably raise blood NAD+ levels and are likely safe at typical doses, but no convincing human trial has shown they improve a clinical outcome you care about — longevity, cognitive function, cardiovascular events. If you choose to take them, understand you are essentially participating in an ongoing natural experiment. The evidence base may change substantially as larger trials complete over the next 5–10 years.

Why did niacin fail in the AIM-HIGH trial despite improving all the lipid numbers?

This is one of the most instructive examples in clinical pharmacology of surrogate marker failure. Niacin raised HDL, lowered triglycerides, and lowered LDL — all in the right direction — but produced no cardiovascular benefit when added to statin therapy. The most plausible explanation is that in patients with well-controlled LDL on statins, residual cardiovascular risk is not primarily driven by HDL or triglyceride levels in ways that pharmacological modification can fix. Raising HDL pharmaceutically may not replicate the cardiovascular benefit of naturally high HDL, which may reflect underlying metabolic health rather than a directly protective molecule.

Can niacin cause liver damage?

Yes, particularly with sustained-release formulations at pharmacological doses. The hepatotoxicity risk is paradoxically higher with slow-release niacin than with immediate-release, apparently because the sustained lower peak concentrations favour a different metabolic pathway that generates more hepatotoxic metabolites. This is an important distinction — slow-release niacin was developed to reduce flushing but inadvertently increased liver risk.

Does niacin interact with medications?

At pharmacological doses, yes. Nicotinic acid increases the risk of myopathy when combined with statins (the combination was used for decades before this risk was better characterised). It can worsen blood glucose control in diabetics. It can raise uric acid and precipitate gout. It can enhance the effect of antihypertensive medications causing hypotension. At nutritional doses from B-complex supplements, significant interactions are uncommon. If considering pharmacological niacin for lipid management, medical supervision is essential.

Evidence base

6 peer-reviewed sources on this topic. Every PMID and DOI below was retrieved from PubMed and resolves. Where a figure in the text above is not attributed to one of these studies, it has not yet been traced to a primary source and is under editorial review.

  1. Palawaththa S, Islam RM, Illic D, et al. Effect of maternal dietary niacin intake on congenital anomalies: a systematic review and meta-analysis. European journal of nutrition 2022.
    doi:10.1007/s00394-021-02731-9PMID 34748060
  2. Xiang D, Zhang Q, Wang YT, et al. Effectiveness of niacin supplementation for patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Medicine 2020.
    doi:10.1097/MD.0000000000021235PMID 32702899
  3. Minto C, Vecchio MG, Lamprecht M, et al. Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation. Nutrition reviews 2017.
    doi:10.1093/nutrit/nux011PMID 28541582
  4. Brakedal B, Dölle C, Riemer F, et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell metabolism 2022.
    doi:10.1016/j.cmet.2022.02.001PMID 35235774
  5. Jenkins DJA, Spence JD, Giovannucci EL, et al. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar. Journal of the American College of Cardiology 2021.
    doi:10.1016/j.jacc.2020.09.619PMID 33509399
  6. Silverman MG, Ference BA, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016.
    doi:10.1001/jama.2016.13985PMID 27673306
Subscribe to Our Newsletter
Subscribe to our newsletter to get our newest articles instantly!
[mc4wp_form]
Share This Article
Facebook Whatsapp Whatsapp LinkedIn Telegram Email Copy Link Print
ByIrina Datashvili
Irina Datashvili is a Senior Medical Journalist at SheniEkimi with expertise in translating complex medical and nutritional research into evidence-based content for general audiences. She covers clinical research, supplement safety, product recalls, and consumer health news. (125 articles)
Previous Article Vitamin A: Retinol, Beta-Carotene, and the Lessons of CARET and ATBC
Next Article Cover graphic for "Thiamine (Vitamin B1)": the article title set in white on a dark green background with a panel showing evidence grade A. Thiamine (Vitamin B1): Deficiency Syndromes, At-Risk Populations, and Supplementation

Georgian Medical Journal

Submit Your Research Paper

Peer-reviewed open-access journal. No article processing charge until January 2027.

Submit Manuscript →

GMJ News

Georgian Medical Journal News

Clinical updates, research digests and public health news from Georgia and beyond.

Read GMJ News →

Editor's Pick

PHIG Position Statement: Orthomol Micronutrient Products Are Not Recommended in Georgia

Date: November 25, 2025 Status: Public health expert position based on independent, publicly available scientific and legal sources PHIG POSITION…

By
Prof. Giorgi Pkhakadze
18 Min Read
Numbness and tingling - illustrative image
Numbness and tingling: what it can mean

Pins and needles in both feet, creeping upward over months, is a…

4 Min Read
Irregular periods - illustrative image
Irregular periods: what they can mean

Cycles that are unpredictable, very infrequent or absent have a short list…

3 Min Read

Top Writers

ekapantskalashvili
mirandadeisadze84

Oponion

Burning when passing urine - illustrative image

Burning when passing urine: what it can mean

Usually a bladder infection. What this site covers about preventing…

13/11/2026

Itchy skin or rash: what it can mean

Where it is, what it looks…

13/11/2026

Excessive thirst: what it can mean

Thirst with passing urine often, especially…

13/11/2026

Sore throat: what it can mean

Nearly always viral and self-limiting. The…

13/11/2026

Headache: what it can mean

Most headache is tension type or…

13/11/2026

Recent Posts

  • PHIG Position Statement: Orthomol Micronutrient Products Are Not Recommended in Georgia
  • Numbness and tingling: what it can mean
  • Irregular periods: what they can mean
  • Burning when passing urine: what it can mean
  • Itchy skin or rash: what it can mean

You Might Also Like

Cover graphic for "Vitamin D": the article title set in white on a dark green background with a panel showing n = 25,871, cited sources PMID 30415629, PMID 35133822.
Ingredient Spotlight

Vitamin D: The Sunshine Hormone — Why Supplements Are Essential for Most People

The VITAL trial (Manson et al., NEJM 2019, PMID 30415629 ; n=25,871; 2000 IU/day vitamin D3 for 5.3 years) reduced…

18 Min Read
Cover for "Omega-3 Fish Oil": a photograph of raw salmon, a source of long-chain omega-3, with the article title set beside it.
Ingredient Spotlight

Omega-3 Fish Oil: 30 Years of Research, One Clear Conclusion

The REDUCE-IT trial (NEJM 2019, PMID 30415628 ; n=8,179) found that 4 g/day of icosapentaenoic acid (EPA, a specific omega-3…

14 Min Read
Ingredient Spotlight

Vitamin A: Vision and Immunity Booster

Vitamin A is crucial for maintaining healthy vision, supporting immune function, and promoting skin health, with significant benefits backed by…

4 Min Read
Cover for "Zinc": a photograph of oysters, the densest dietary source of zinc, with the article title set beside it.
Ingredient SpotlightMinerals

Zinc: Immune Support, Deficiency Diagnosis, and Upper Limit Concerns

Zinc is essential for immune function, wound healing, taste and smell, and over 300 enzymatic reactions. This evidence-based review examines…

9 Min Read

News

Technology

Health

Culture

More

Subscribe

  • Home Delivery
  • Digital Subscription
  • Games
  • Cooking

All Rights Reserved.nn

© 2026 Supplement.ge | Published by the Public Health Institute of Georgia (PHIG)
Supplement.geSupplement.ge
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

supplement.ge

Georgia’s independent evidence-based supplement reference database. Science-first. Editorial independence guaranteed.

Facebook | X | YouTube

Navigate

  • Home
  • News
  • Supplement Database
  • Safety & Recalls
  • About
  • Contact

Legal & Policies

  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Terms of Use
  • Data Transparency
  • Editorial Standard

PHIG Network

  • Georgian Medical Journal
  • GMJ Academic Journal
  • PHIG.ge
© 2026 supplement.ge | Published by the Public Health Institute of Georgia (PHIG) | Editorial independence: supplement.ge does not accept payment for editorial coverage.